A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs DNL-747 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 08 Jan 2020 Status changed from active, no longer recruiting to completed.
- 20 Nov 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 20 Nov 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.